Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

Prostate

Volumn 71, Issue 8, 2011, Pages 899-907

  Almasi, Charlotte E ^a   Brasso, Klaus ^b   Iversen, Peter ^b   Pappot, Helle ^b   Høyer Hansen, Gunilla ^a   Danø, Keld ^a   Christensen, Ib J ^a  

^a FINSEN LABORATORY   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Prediction; Prognosis; Prostate cancer; Time resolved fluorescence immunoassays; uPAR

Indexed keywords

ESTROGEN; FLUTAMIDE; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); HUMAN; IMMUNOASSAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; ORCHIECTOMY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL; TIME RESOLVED FLUORESCENCE IMMUNOASSAY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; CARCINOMA; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79953687971     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21306     Document Type: Article

References (47)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. American Cancer Society. Cancer Facts & Figures. 2006.
4. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL III, Bennett CL, Scher HI. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596-1605.
5. NormanG, Dean ME, Langley RE, Hodges ZC, Ritchie G, Parmar MK, Sydes MR, Abel P, Eastwood AJ, et al. Parenteral oestrogen in the treatment of prostate cancer: A systematic review. Br J Cancer 2008;98:697-707. (Pubitemid 351272616)
6. Collette L, De Reijke TM, Schroder FH. Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2003;44:182-189. (Pubitemid 36917001)
7. Oh K, Hurwitz M, D'Amico A, Richie J, Kantoff P. Neoplasms of the prostate. Cancer Medicine, 6th edition, NCBI edition. United States: BC Decker; 2008.
8. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: Data from CaPSURE. Cancer 2007;110:81-86. (Pubitemid 46986421)
9. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195-202. (Pubitemid 18023133)
10. Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: Comparison with the extent of disease (EOD) grade. Prostate 1999;38:28-34. (Pubitemid 29011014)
11. Lilja H, Vickers A, Scardino P. Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer. J Clin Oncol 2007;25:347-348. (Pubitemid 350002981)
12. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005;92:2171-2180. (Pubitemid 40966253)
13. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40. (Pubitemid 30105328)
14. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-681. (Pubitemid 40485402)
15. Høyer-Hansen G, Rønne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Danø K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992;267:18224-18229.
16. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cellsurface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997;243:21-26. (Pubitemid 27060380)
17. Zhou HM, Nichols A, Meda P, Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000;19:4817-4826.
18. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994;344:401-402. (Pubitemid 24248215)
19. Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-1087.
20. Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-4675. (Pubitemid 24276492)
21. Plebani M, Herszenyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F. Urokinase-type plasminogen activator receptor in gastric cancer: Tissue expression and prognostic role. Clin Exp Metastasis 1997;15:418-425. (Pubitemid 27285815)
22. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002;8:1132-1141. (Pubitemid 34517650)
23. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 1999;91:869-874. (Pubitemid 29252303)
24. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-355. (Pubitemid 350002982)
25. Piironen T, Laursen B, Pass J, List K, Gårdsvoll H, Ploug M, Danø K, Høyer-Hansen G. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004;50:2059-2068.
26. Almasi CE, Høyer-Hansen G, Christensen IJ, Danø K, Pappot H. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005;48:349-355. (Pubitemid 40693620)
27. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785-5793.
28. Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brünner N, Danø K, Høyer-Hansen G, Lilja H. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006;52:838-844. (Pubitemid 43673262)
29. Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000;55:328-333.
30. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P. Prognostic value of PINP, bone alkaline phosphatase, CTX-1, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66:503-513.
31. Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J. SPCG-5 Study Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42:220-229. (Pubitemid 351574386)
32. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 2007; 13:3244-3249. (Pubitemid 46944908)
33. Almasi CE, Høyer-Hansen G, Christensen IJ, Pappot H. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009;117:755-761.
34. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39:123-129. (Pubitemid 29194284)
35. Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Hansson E, Juusela H, Permi J, Saarialho M, Viitanen J, Alfthan O. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer. Br J Urol 1991;67:184-187.
36. Lukkarinen O, Kontturi M. Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study. Scand J Urol Nephrol 1994;28:171-178. (Pubitemid 24205376)
37. Mikkola A, Aro J, Rannikko S, Ruutu M. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. Prostate 2007;67:447-455. (Pubitemid 46341087)
38. Høyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007;44:65-102.
39. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995;154:1991-1998.
40. Ho SM. Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91:491-503.
41. Pousette A, Carlstrom K, Henriksson P, Grande M, Stege R. Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research. Prostate 1997; 31:198-203. (Pubitemid 27225205)
42. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA. Estrogendependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100:815-825. (Pubitemid 351809667)
43. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. TMPRS S2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26: 4596-4599. (Pubitemid 47037039)
44. Usher PA, Thomsen OF, Iversen P, Johnsen M, Brünner N, Høyer-Hansen G, Andreasen P, Danø K, Nielsen BS. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005;113:870-880. (Pubitemid 40096866)
45. Cunha GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 2004;67: 417-434. (Pubitemid 40424552)
46. Risbridger GP, Ellem SJ, McPherson SJ. Estrogen action on the prostate gland: A critical mix of endocrine and paracrine signaling. J Mol Endocrinol 2007;39:183-188. (Pubitemid 350047640)
47. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001;314:241-244. (Pubitemid 33079205)